Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

1.

Beyond monoamines: glutamatergic function in mood disorders.

Kugaya A, Sanacora G.

CNS Spectr. 2005 Oct;10(10):808-19. Review.

PMID:
16400244
[PubMed - indexed for MEDLINE]
2.

Glutamatergic modulators: the future of treating mood disorders?

Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G.

Harv Rev Psychiatry. 2010 Sep-Oct;18(5):293-303. doi: 10.3109/10673229.2010.511059. Review.

PMID:
20825266
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.

Machado-Vieira R, Manji HK, Zarate CA.

Neuroscientist. 2009 Oct;15(5):525-39. doi: 10.1177/1073858409336093. Epub 2009 May 26. Review. Erratum in: Neuroscientist. 2010 Apr;16(2):199.

PMID:
19471044
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

[The role of the glutamatergic system in pathophysiology and pharmacotherapy for depression: preclinical and clinical data].

Paslakis G, Gass P, Deuschle M.

Fortschr Neurol Psychiatr. 2011 Apr;79(4):204-12. doi: 10.1055/s-0029-1245770. Epub 2010 Nov 29. Review. German.

PMID:
21117011
[PubMed - indexed for MEDLINE]
5.

The role of glutamate on the action of antidepressants.

Hashimoto K.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15;35(7):1558-68. doi: 10.1016/j.pnpbp.2010.06.013. Epub 2010 Jun 20. Review.

PMID:
20600468
[PubMed - indexed for MEDLINE]
6.

Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.

Banasr M, Chowdhury GM, Terwilliger R, Newton SS, Duman RS, Behar KL, Sanacora G.

Mol Psychiatry. 2010 May;15(5):501-11. doi: 10.1038/mp.2008.106. Epub 2008 Sep 30.

PMID:
18825147
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.

Owen RT.

Drugs Today (Barc). 2012 Jul;48(7):469-78. doi: 10.1358/dot.2012.48.7.1832873. Review.

PMID:
22844658
[PubMed - indexed for MEDLINE]
8.

Novel glutamatergic drugs for the treatment of mood disorders.

Lapidus KA, Soleimani L, Murrough JW.

Neuropsychiatr Dis Treat. 2013;9:1101-12. doi: 10.2147/NDT.S36689. Epub 2013 Aug 7.

PMID:
23976856
[PubMed]
Free PMC Article
9.

Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.

Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF.

Mol Psychiatry. 2002;7 Suppl 1:S71-80. Review.

PMID:
11986998
[PubMed - indexed for MEDLINE]
Free Article
10.

Metabotropic glutamate receptors in the control of mood disorders.

Witkin JM, Marek GJ, Johnson BG, Schoepp DD.

CNS Neurol Disord Drug Targets. 2007 Apr;6(2):87-100. Review.

PMID:
17430147
[PubMed - indexed for MEDLINE]
11.

Targeting glial physiology and glutamate cycling in the treatment of depression.

Valentine GW, Sanacora G.

Biochem Pharmacol. 2009 Sep 1;78(5):431-9. doi: 10.1016/j.bcp.2009.04.008. Epub 2009 Apr 17.

PMID:
19376090
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Employing pharmacologic treatment of bipolar disorder to greatest effect.

Schatzberg AF.

J Clin Psychiatry. 2004;65 Suppl 15:15-20. Review.

PMID:
15554791
[PubMed - indexed for MEDLINE]
13.

Novel glutamatergic agents for major depressive disorder and bipolar disorder.

Machado-Vieira R, Ibrahim L, Henter ID, Zarate CA Jr.

Pharmacol Biochem Behav. 2012 Feb;100(4):678-87. doi: 10.1016/j.pbb.2011.09.010. Epub 2011 Sep 25. Review.

PMID:
21971560
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression.

Zarate CA Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney DS, Manji HK.

Biol Psychiatry. 2005 Feb 15;57(4):430-2.

PMID:
15705360
[PubMed - indexed for MEDLINE]
15.

[Hepatitis C, interferon a and depression: main physiopathologic hypothesis].

Vignau J, Karila L, Costisella O, Canva V.

Encephale. 2005 May-Jun;31(3):349-57. Review. French.

PMID:
16142050
[PubMed - indexed for MEDLINE]
16.

Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.

Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH.

Biol Psychiatry. 2007 Mar 15;61(6):822-5. Epub 2006 Dec 4.

PMID:
17141740
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Riluzole in the treatment of mood and anxiety disorders.

Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G.

CNS Drugs. 2008;22(9):761-86. Review.

PMID:
18698875
[PubMed - indexed for MEDLINE]
18.

The role of glutamate in anxiety and related disorders.

Cortese BM, Phan KL.

CNS Spectr. 2005 Oct;10(10):820-30. Review.

PMID:
16400245
[PubMed - indexed for MEDLINE]
19.

Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Yüksel C, Öngür D.

Biol Psychiatry. 2010 Nov 1;68(9):785-94. doi: 10.1016/j.biopsych.2010.06.016. Epub 2010 Aug 21. Review.

PMID:
20728076
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.

Sanacora G, Treccani G, Popoli M.

Neuropharmacology. 2012 Jan;62(1):63-77. doi: 10.1016/j.neuropharm.2011.07.036. Epub 2011 Aug 3. Review.

PMID:
21827775
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk